Aoife Brennan
Director/Miembro de la Junta en FIBROGEN, INC. .
Fortuna: 47 572 $ al 30/04/2024
Cargos activos de Aoife Brennan
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
FIBROGEN, INC. | Director/Miembro de la Junta | 05/08/2020 | - |
Synlogic Operating Co., Inc.
Synlogic Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Synlogic Operating Co., Inc. operates as a biopharmaceutical company. The firm's pipeline focuses on rare diseases, the company is leveraging the broad potential of its synthetic biotics platform for novel drug development in major disease areas through partnerships with pharmaceutical and biotechnology companies. It also engages in development of synthetic biotics-based treatment for inflammatory bowel disease. The company was founded by James J. Collins and Timothy K. Lu in 2014 and is headquartered in Cambridge, MA. | Director/Miembro de la Junta | - | - |
Director Ejecutivo | 01/05/2018 | - | |
Presidente | 01/05/2018 | - | |
Director Técnico/Científico/I+D | 01/09/2016 | - | |
Cerevance, Inc.
Cerevance, Inc. Medical SpecialtiesHealth Technology Cerevance, Inc. provides pharmaceutical services. The firm discovers new treatments for central nervous system diseases. Its platform enables to profile specific brain cell types including both neurons and glial cells in mature human brain tissue. The company was founded by Bradley A. Margus and Mark Carlton in 2016 and is headquartered in Boston, MA. | Director/Miembro de la Junta | 01/01/2020 | - |
Atlas Venture Advisors, Inc.
Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Consultor / Asesor | - | - |
Historial de carrera de Aoife Brennan
Antiguos cargos conocidos de Aoife Brennan.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
SYNLOGIC, INC. | Director/Miembro de la Junta | 01/10/2018 | 09/03/2024 |
Director Ejecutivo | 10/05/2018 | 09/03/2024 | |
Director Técnico/Científico/I+D | 01/09/2016 | 04/09/2019 | |
Presidente | 10/05/2018 | 09/03/2024 | |
RA PHARMACEUTICALS, INC. | Director/Miembro de la Junta | 25/09/2018 | 02/04/2020 |
Independent Dir/Board Member | 25/09/2018 | 02/04/2020 | |
BIOGEN INC. | Corporate Officer/Principal | 01/05/2011 | 01/08/2016 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | Corporate Officer/Principal | 01/01/2008 | 01/04/2011 |
Formación de Aoife Brennan.
Trinity College Dublin | Doctorate Degree |
Harvard Medical School | Graduate Degree |
Estadísticas
Internacional
Estados Unidos | 10 |
Irlanda | 2 |
Operativa
Director/Board Member | 5 |
Chief Executive Officer | 2 |
Chief Tech/Sci/R&D Officer | 2 |
Sectorial
Health Technology | 8 |
Consumer Services | 3 |
Finance | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 3 |
---|---|
SYNLOGIC, INC. | Health Technology |
BIOGEN INC. | Health Technology |
FIBROGEN, INC. | Health Technology |
Empresas privadas | 5 |
---|---|
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | Health Technology |
Ra Pharmaceuticals, Inc.
Ra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ra Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of peptide-based drugs. It uses Extreme Diversity platform that allows to produce synthetic macrocyclic peptides. The company was founded by James W. Broderick and Douglas A. Treco on June 27, 2008 and is headquartered in Cambridge, MA. | Health Technology |
Synlogic Operating Co., Inc.
Synlogic Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Synlogic Operating Co., Inc. operates as a biopharmaceutical company. The firm's pipeline focuses on rare diseases, the company is leveraging the broad potential of its synthetic biotics platform for novel drug development in major disease areas through partnerships with pharmaceutical and biotechnology companies. It also engages in development of synthetic biotics-based treatment for inflammatory bowel disease. The company was founded by James J. Collins and Timothy K. Lu in 2014 and is headquartered in Cambridge, MA. | Health Technology |
Cerevance, Inc.
Cerevance, Inc. Medical SpecialtiesHealth Technology Cerevance, Inc. provides pharmaceutical services. The firm discovers new treatments for central nervous system diseases. Its platform enables to profile specific brain cell types including both neurons and glial cells in mature human brain tissue. The company was founded by Bradley A. Margus and Mark Carlton in 2016 and is headquartered in Boston, MA. | Health Technology |
Atlas Venture Advisors, Inc.
Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Finance |
- Bolsa de valores
- Insiders
- Aoife Brennan
- Experiencia